Chronic myeloid leukemia stem cells and developing therapies

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 1, 2011, Pages 60-80

  Donato, Nicholas J ^a   Peterson, Luke F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; inhibitors; signaling pathways; stem cell; therapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 3 METHYLADENINE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AP 25534; ARSENIC TRIOXIDE; BAFETINIB; BORTEZOMIB; BOSUTINIB; CCI 079; CHLOROQUINE; CYCLOPAMINE; CYTARABINE; DACINOSTAT; DASATINIB; EVEROLIMUS; FINGOLIMOD; FORSKOLIN; HOMOHARRINGTONINE; IMATINIB; IPI 926; NILOTINIB; NVP LDE 225; OBATOCLAX; OBLIMERSEN; OSI 027; PANOBINOSTAT; PEGINTERFERON; PF 04449913; PP 242; PYRVINIUM EMBONATE; RAPAMYCIN; RETASPIMYCIN; TRIPTOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WP 1130; XAV 939; ZILEUTON;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; CANCER STEM CELL; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SRC HOMOLOGY DOMAIN;

ANIMALS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 79951502127     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546921     Document Type: Review

References (208)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-4817.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology ofchronic myeloid leukemia. N Engl J Med 1999;341:164-172.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. (Pubitemid 32267972)
5. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006;10: 425-435. (Pubitemid 44693471)
6. Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009:461-476.
7. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechan-isms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009;16:122-131.
8. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-848. (Pubitemid 47500507)
9. Martinelli G, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. Best Pract Res Clin Haematol 2009;22:445-454.
10. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-412.
11. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program 2009;477-487.
12. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009;453-460.
13. Radich JP. Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting. Clin Lymphoma Myeloma 2009;9(Suppl. 4):S391-S394.
14. Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 2010 Oct 19. [Epub ahead ofprint].
15. Savona M, Talpaz M. Getting to the stem ofchronic myeloid leukaemia. Nat Rev Cancer 2008;8:341-350. (Pubitemid 351589698)
16. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
17. Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010;24:1545-1554.
18. Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol 2010;47:362-370.
19. Copland M. Chronic myelogenous leukemia stem cells: what's new? Curr Hematol Malig Rep 2009;4:66-73.
20. Helgason GV, Young GA, Holyoake TL. Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep 2010;5:81-87.
21. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111. (Pubitemid 33041634)
22. Eaves CJ. Cancer stem cells: here, there, everywhere? Nature 2008;456:581-582.
23. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737. (Pubitemid 27298715)
24. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648. (Pubitemid 24067706)
25. Wang JC, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic mye-loid leukemia in chronic phase. Blood 1998;91:2406-2414. (Pubitemid 28155515)
26. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft im-munodeficient mice and produce a model of the human disease. Leukemia 2005;19:435-441. (Pubitemid 40403322)
27. Cross NCP, Daley GQ, Green AR, et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproli-ferative disorders: some common and contrasting features. Leukemia 2008;22:1975-1989.
28. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667. (Pubitemid 39063268)
29. Koschmieder S, Gottgens B, Zhang P, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABLleukemogenesis. Blood 2005;105:324-334. (Pubitemid 40053100)
30. Perez-Caro M, Cobaleda C, Gonzalez-Herrero I, et al. Cancer induction by restriction ofoncogene expression to the stem cell compartment. EMBO J 2009;28:8-20.
31. Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46: 1039-1050. (Pubitemid 47502843)
32. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110-114. (Pubitemid 351630327)
33. Gunsilius E, Duba H-C, Petzer AL, et al. Evidence from a leukaemia model for maintenance ofvascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000;355: 1688-1691. (Pubitemid 30248482)
34. Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitor cells with heman-gioblastic characteristics. Blood 2005;105:2733-2740. (Pubitemid 40446263)
35. Wu J, Huang L, Huang M, et al. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp Hematol 2009;37:87-91.
36. Otten J, Schultze A, Schafhausen P, et al. Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. BrJHaematol 2008;142:115-118. (Pubitemid 351783163)
37. Engelhardt M, Lubbert M, Guo Y. CD34(+) or CD34(\): which is the more primitive? Leukemia 2002;16:1603-1608.
38. Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34-cell population with intrinsic resistance to imatinib. Blood 2009; 114:5191-5200.
39. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete mole-cular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719-1724.
40. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007;18:459-471. (Pubitemid 47302836)
41. Lee MS, Kantarjian H, Talpaz M, et al. Detection ofminimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia follow-ing interferon therapy. Blood 1992;79:1920-1923.
42. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 1995;91:126-131.
43. Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? Leukemia 2010 Sep 16. [Epub ahead ofprint].
44. Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hemato-poietic stem cells. Blood 2010;115:3185-3195.
45. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009;114:1150-1157.
46. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009;12: 103-113.
47. Wang P-Y, Young F, Chen C-Y, et al. The biological properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood 2008;112:4184-4192.
48. Yamazaki S, Iwama A, Takayanagi S, Eto K, Ema H, Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009;113:1250-1256.
49. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463:676-680.
50. Mulloy JC, Cancelas JA, Filippi M-D, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010;115:936-947.
51. Sahay S, Pannucci NL, Mahon GM, et al. The RhoGEF domain ofp210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008;27:2064-2071. (Pubitemid 351442739)
52. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007;12:467-478. (Pubitemid 350046406)
53. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010;116:81-84.
54. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528-541. (Pubitemid 350199070)
55. Hu Y, Chen Y, Douglas L, Li S. Beta-catenin is essential for survival ofleukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23:109-116.
56. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238-249.
57. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-779.
58. Mizuno T, Yamasaki N, Miyazaki K, et al. Overexpression/enhanced kinase activity ofBCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCRABL transgenic mice. Oncogene 2008;27:3465-3474. (Pubitemid 351769317)
59. Nakahara F, Sakata-Yanagimoto M, Komeno Y, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 2010;115:2872-2881.
60. Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood 2008;111:492-503.
61. Ter Huurne M, Figdor CG, Torensma R. Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche. Stem Cells Dev 2010;19:1131-1141.
62. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010;7:150-161.
63. Eliasson P, Jönsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010;222:17-22.
64. Takeuchi M, Kimura S, Kuroda J, et al. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 2010;17:1211-1220.
65. Klawitter J, Kominsky DJ, Brown JL, et al. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol 2009;158:588-600.
66. Zhao F, Mancuso A, Bui TV, et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010;29:2962-2972.
67. Wittig R, Coy JF. The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Medicin Chem 2008;1:64-82.
68. Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010;7:380-390.
69. Semenza GL. Defining the role ofhypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009;29:625-634.
70. Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 2010;7:391-402.
71. Parmar K, Mauch P, Vergilio J-A, Sackstein R, Down JD. Distribution ofhematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007;104:5431-5436. (Pubitemid 47175697)
72. Winkler IG, Barbier V, Wadley R, Zannettino ACW, Williams S, Levesque J-P. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010;116:375-385.
73. Kaufman DS. HIF hits Wnt in the stem cell niche. Nat Cell Biol 2010;12:926-927.
74. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-482. (Pubitemid 351766797)
75. Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogram-ming ofcancer cell metabolism. Cancer Res 2009;69:2163-2166.
76. Kim Y-W, Koo B-K, Jeong H-W, et al. Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood 2008;112:4628-4638.
77. Walkley CR, Olsen GH, Dworkin S, et al. A microenviron-ment-induced myeloproliferative syndrome caused by reti-noic acid receptor gamma deficiency. Cell 2007;129:1097-1110. (Pubitemid 46908696)
78. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475-482. (Pubitemid 44050144)
79. Raaijmakers MHGP, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and second-ary leukaemia. Nature 2010;464:852-857.
80. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126-139.
81. Mani R-S, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
82. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-1083.
83. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010;7:174-185.
84. Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010;7:186-197.
85. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008;13:483-495. (Pubitemid 351763903)
86. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766-774.
87. O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-1689. (Pubitemid 351235134)
88. Fitter S, Dewar A, Kostakis P. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111: 2538-2547.
89. Tibullo D, Giallongo C, La Cava P. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009;37:461-468.
90. Vandyke K, Dewar A, Farrugia A. Therapeutic concentra-tions of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994-997.
91. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008;7:48-58.
92. Chute JP. Stem cell homing. Curr Opin Hematol 2006;13: 399-406. (Pubitemid 44607440)
93. Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med 2002;196:667-678. (Pubitemid 35024444)
94. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol 2008;26:2911-2915.
95. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
96. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707. (Pubitemid 36857723)
97. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leuke-mia in complete molecular remission for more than 2 years. Blood 2007;109:58-60. (Pubitemid 46053043)
98. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006;103:16870-16875. (Pubitemid 44737345)
99. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539. (Pubitemid 43801382)
100. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CMLcells. Blood 2007;109:4016-4019. (Pubitemid 46641755)
101. Wu J, Meng F, Kong LY, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008;100:926-939. (Pubitemid 351957515)
102. Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306-314. (Pubitemid 46053071)
103. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004;279:34227-34239. (Pubitemid 39318046)
104. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698. (Pubitemid 36077594)
105. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 path-way, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009;28:1669-1681.
106. Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008;111:3821-3829.
107. Zimmerman EI, Dollins CM, Crawford M, et al. Lyn kinase-dependent regulation ofmiR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol 2010;78:811-817.
108. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-461. (Pubitemid 38620028)
109. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009;106:3925-3929.
110. Coluccia AM, Vacca A, Dunach M, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007;26:1456-1466. (Pubitemid 46398694)
111. Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006;25:7482-7491. (Pubitemid 44885747)
112. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis ofchronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843-2853.
113. Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B, Holyoake TL. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38-cells, through activation of protein kinase Cbeta. Blood 2009;114:4186-4196.
114. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-160.
115. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-368. (Pubitemid 41579831)
116. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelo-genous leukaemia. Br J Cancer 2006;95:775-781. (Pubitemid 44500626)
117. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-2421. (Pubitemid 47494343)
118. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39. (Pubitemid 28458022)
119. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-3050.
120. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868. (Pubitemid 29165088)
121. Miyamoto K, Araki KY, Naka K, et al. foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007;1:101-112. (Pubitemid 46865800)
122. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463:676-680.
123. Peng C, Chen Y, Yang Z, et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010;115:626-635.
124. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-3050.
125. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205-213.
126. Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469-12474.
127. Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition ofBcr-Abl. Cancer Cell 2010;18:74-87.
128. Abdel-Azim H, Zhu Y, Hollis R, et al. Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood 2008;111:4064-4074.
129. Chen Y, Hu Y, Zhang H, Peng C,LiS. Loss ofthe Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783-792.
130. DuBois RN. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst 2003;95:1028-1029.
131. Anderson KM, Seed T, Jajeh A, et al. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration in-duces apoptosis in U937 and CML cells. Anticancer Res 1996;16:2589-2599. (Pubitemid 26388222)
132. Anderson KM, Seed T, Plate JM, Jajeh A, Meng J, Harris JE. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apopto-sis. Leuk Res 1995;19:789-801. (Pubitemid 26009887)
133. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794-2799.
134. Graham SM, Vass JK, Holyoake TL, Graham GJ. Tran-scriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007;25:3111-3120. (Pubitemid 350294437)
135. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. The mechanisms ofPML-nuclear body formation. Mol Cell 2006;24:331-339.
136. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072-1078. (Pubitemid 351871736)
137. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010;9:3470-3478.
138. Bellodi C. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109-1123.
139. Salomoni P, Calabretta B. Targeted therapies and autop-hagy: new insights from chronic myeloid leukemia. Autophagy 2009;5:1050-1051.
140. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069. (Pubitemid 16137079)
141. Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010;95:1415-1419.
142. Le Coutre P, Schwarz M, Kim TD. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin CancerRes 2010;16:1771-1780.
143. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-1435.
144. Pitini V, Arrigo C, Altavilla G. How cells respond to interferons. J Clin Oncol 2010;28:e439; author reply e440.
145. Stark GR. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev 2007;18:419-423. (Pubitemid 47302834)
146. Essers MAG, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-908.
147. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the 'best' therapy? Curr Oncol Rep 2010;12:302-313.
148. Fava C, Saglio G. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? Semin Hematol 2010;47:319-326.
149. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
150. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280: 192-200.
151. Bradbury CA, Khanim FL, Hayden R, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-1759. (Pubitemid 41486152)
152. Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010;17:427-442.
153. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identifica-tion of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileu-kemic effects of imatinib and mcl-1 antisense oligonucleo-tides. Blood 2005;105:3303-3311.
154. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role ofBCRABL, characterization ofunderlying signaling path-ways, and reexpression by novel pharmacologic compounds. Cancer Res 2005;65:9436-9444. (Pubitemid 41508012)
155. Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechan-isms. Br J Haematol 2008;140:181-190. (Pubitemid 350265045)
156. Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007;14:1667-1677. (Pubitemid 47278852)
157. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907-14912. (Pubitemid 44527827)
158. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat 2007;10:207-217. (Pubitemid 351163146)
159. Campbell CJ, Lee JB, Levadoux-Martin M, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010;116:1433-1442.
160. Lu M, Wang J, Li Y, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F positive polycythemia vera hematopoietic progenitor cells. Blood 2010;116:4284-4287.
161. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10: 375-388. (Pubitemid 44693472)
162. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-8301.
163. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lym-phocytic leukemia. Blood 2009;113:299-305.
164. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-5438. (Pubitemid 46890566)
165. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination ofMcl-1 and regulates apoptosis. Cell 2005;121:1085-1095. (Pubitemid 40884398)
166. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-107.
167. Bartholomeusz GA, Talpaz M, Kapuria V, et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007;109:3470-3478. (Pubitemid 46572537)
168. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010;70:9265-9276.
169. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
170. Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006;6:1163-1171. (Pubitemid 44110927)
171. Porter JR, Fritz CC, Depew KM. Discovery and develop-ment of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010;14:412-420.
172. Peng C, Li D, Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007;6:2227-2231. (Pubitemid 47547697)
173. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival ofmice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110:678-685. (Pubitemid 47105407)
174. Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010;115:2241-2250.
175. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010;116:81-84.
176. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol 2006;406:554-565. (Pubitemid 43207468)
177. Gu Y, Filippi MD, Cancelas JA, et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003;302:445-449. (Pubitemid 37296270)
178. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 2010;95:900-907.
179. Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res 2009;69:9481-9489.
180. Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010;6:829-836.
181. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-620.
182. Takahashi-Yanaga F, Sasaguri T. Drug development target-ing the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J Pharmacol Sci 2009;109:179-183.
183. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-897.
184. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008;27:159-168.
185. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009;23:1432-1440.
186. Kharas MG, Fruman DA. ABL oncogenes and phosphoi-nositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-2053. (Pubitemid 40490106)
187. Kong D, Yamori T. Advances in development ofphospha-tidylinositol 3-kinase inhibitors. Curr Med Chem 2009;16: 2839-2854.
188. Cheng GZ, Park S, Shu S, et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 2008; 8:2-6. (Pubitemid 351237904)
189. Yoon P, Giafis N, Smith J, et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 2006;5: 2815-2823. (Pubitemid 44849008)
190. Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med 2009;361:1202-1205.
191. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010;466:765-768.
192. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010;16:903-908.
193. Sengupta A, Banerjee D, Chandra S, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007;21:949-955. (Pubitemid 46672071)
194. Chen Y, Li D, Li S. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle 2009;8:3488-3492.
195. Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-676. (Pubitemid 46449830)
196. Emadi A, Gore SD. Arsenic trioxide-an old drug rediscovered. Blood Rev 2010;24:191-199.
197. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109-1123.
198. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116:1329-1335.
199. Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 2003;9:4267-4273. (Pubitemid 37204048)
200. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancercells. Oncogene 2008;27(Suppl. 1):S149-S157.
201. Genin E, Reboud-Ravaux M, Vidal J. Proteasome inhibitors: recent advances and new perspectives in medicinal chem-istry. CurrTop Med Chem 2010;10:232-256.
202. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002;7:277-288. (Pubitemid 35291458)
203. Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24:699-705.
204. Quintas-Cardama A, Cortes J. Omacetaxine mepesuccinate-a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs 2008;11:356-372. (Pubitemid 351677896)
205. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446-1454.
206. Mak DH, Schober WD, Chen W, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009;8:2509-2516.
207. Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I muta-tion. Clin Cancer Res 2009;15:1686-1697.
208. Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009;45:1764-1772.